Colorectal cancer (CRC) is the third most common malignant tumor in humans. Chemotherapy is used for the treatment of CRC. However, the effect of chemotherapy remains unsatisfactory due to drug resistance. Growing evidence has shown that the presence of highly metastatic tumor stem cells, regulation of non-coding RNAs and the tumor microenvironment contributes to drug resistance mechanisms in CRC. Wnt/β-catenin signaling mediates the chemoresistance of CRC in these three aspects. Therefore, the present study analyzed the abundant evidence of the contribution of Wnt/β-catenin signaling to the development of drug resistance in CRC and discussed its possible role in improving the chemosensitivity of CRC, which may provide guidelines for its clinical treatment. Contents 1. Introduction 2. Method 3. Wnt/β-catenin signaling pathway 4. Wnt/β-catenin signaling in CRC drug resistance 5. Wnt inhibitors reduce the resistance of CRC 6. The role of Wnt/β-catenin signaling crosstalk in resistance 7. Conclusions

No abstract

No abstract

No abstract